New vaccine aims to block deadly botulism toxin

NCT ID NCT05348993

Completed Prevention Sponsor: U.S. Army Medical Research and Development Command Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental vaccine (G03-52-01) in 622 healthy adults to see if it could safely protect against botulinum toxin, the poison that causes botulism. Participants received either the vaccine or a placebo, and researchers measured side effects and immune responses. The goal was to find a dose that produces enough protective antibodies to neutralize the toxin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BOTULINUM TOXIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

botulism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BOTULINUM TOXIN HEALTHY

Contacts and locations

Locations

AMR El Dorado

El Dorado, Kansas, 67042, United States
AMR Fort Myers

Fort Myers, Florida, 33912, United States
AMR Kansas City

Kansas City, Missouri, 64114, United States
AMR Knoxville West

Knoxville, Tennessee, 37909, United States
AMR Las Vegas

Las Vegas, Nevada, 89119, United States
AMR Lexington

Lexington, Kentucky, 40509, United States
AMR Miami

Miami, Florida, 33134, United States
AMR Mobile

Mobile, Alabama, 36608, United States
AMR New Orleans

New Orleans, Louisiana, 70119, United States
AMR Newton

Newton, Kansas, 67114, United States
AMR Norfolk

Norfolk, Virginia, 23502, United States
AMR Norman

Norman, Oklahoma, 73069, United States
AMR Tempe

Tempe, Arizona, 85281, United States
AMR Wichita East

Wichita, Kansas, 67207, United States
AMR Wichita West

Wichita, Kansas, 67205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.